Literature DB >> 2228828

Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.

D Van Caekenberghe1.   

Abstract

The in-vitro activities of eight new quinolones (A-56620, amifloxacin, difloxacin, CI-934, enoxacin, irloxacin, pefloxacin, temafloxacin), two reference fluoroquinolones (ciprofloxacin and ofloxacin) and fusidic acid against 147 mycobacterial strains, belonging to seven different species, were compared. Temafloxacin, ofloxacin and ciprofloxacin were the most active compounds. They only showed consistent activity against Mycobacterium tuberculosis, M. malmoense and M. fortuitum, but not against M. chelonei, M. avium, M. intracellulare and M. scrofulaceum. However, individual strains of these species were sometimes susceptible. The best overall in-vitro activity was obtained with temafloxacin, which often showed activity where other products were inactive. Fusidic acid merely displayed good activity against M. tuberculosis (MIC90 16 mg/l).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228828     DOI: 10.1093/jac/26.3.381

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae.

Authors:  S G Franzblau; A N Biswas; E B Harris
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria.

Authors:  R J Wallace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

3.  Lesser known mycobacteria.

Authors:  B Watt
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

4.  Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin.

Authors:  Godwin Akpeko Dziwornu; Stephanie Kamunya; Tando Ntsabo; Kelly Chibale
Journal:  Medchemcomm       Date:  2019-04-18       Impact factor: 3.597

5.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

6.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis.

Authors:  Sinem Akcali; Suheyla Surucuoglu; Candan Cicek; Beril Ozbakkaloglu
Journal:  Ann Saudi Med       Date:  2005 Sep-Oct       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.